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What’s known on the subject? and What does the study add?
A consensus statement published in 2011 summarised current research, clinical approaches, and treatment options for
nocturia. Since that time, new research has reﬁned our understanding of nocturia in clinically important ways and new
evidence has been presented on the eﬃcacy and outcomes of several treatment methods for this underreported,
infrequently recognised, and undertreated problem in adults. This paper provides updated guidance to clinicians in light
of recent advances in the ﬁeld.
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Introduction
Nocturia, awaking to void urine, is a common and
sometimes bothersome symptom that may impose
detrimental impacts on sleep-quality, mood, and overall
health [1]. The multi-factorial aetiology of nocturia,
coupled with the recent demonstration that this symptom
is highly variable over time and often resolves
spontaneously [2] , makes nocturia a challenging clinical
entity. Although nocturia may have little health impact for
some, for others it can be a highly bothersome, debilitating
condition. Multiple studies have shown an association
between nocturia and disturbed sleep, reduced well-being,
and increased morbidity [3–5].
A consensus statement published in 2011 provided
guidance to clinicians who are confronted with the wide
range of clinical presentations of nocturia [1]. That paper
focused primarily on a description of nocturia, its
prevalence, its impact on health-related quality of life
(QOL) and overall health, and an overview of available
treatment options. The present paper extends and
elaborates on the previous paper by examining the most
recent research on diagnostic and treatment outcomes.
Numerous papers have been published in the 2 years since
the previous conference was organised, and the ﬁeld, as a
whole, has a large and dynamic research agenda. This paper
summarises the ﬁndings resulting from a 2012 conference
of key thought leaders in the ﬁeld of nocturia who focused
on updating outcome studies published since the previous
conference was held.
Methods
In June, 2012, an interdisciplinary conference on nocturia
was convened by the New England Research Institutes, Inc.
(NERI), in Cambridge, MA, USA. The goal of the 2-day
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conference was to update and expand upon the conclusions
of a consensus conference on nocturia held in May, 2010.
The 2012 conference focused on aspects of nocturia that
have changed since the previous conference, principally in
details of the management of nocturia. The goal was to
summarise outcome data on the assessment and treatment
of nocturia and to publish the ﬁndings for the beneﬁt of
primary care providers, urologists, and other health
professionals who may treat patients with nocturia.
In all, 11 panellists were selected based on their research or
clinical expertise in nocturia or nocturia-related symptoms,
as well as their position as ‘thought leaders’ in this ﬁeld.
The panellists represented a wide range of disciplinary
backgrounds, including urology, urogynaecology,
psychometrics, primary care, and sleep physiology. Full
attendance at the conference was required.
The panellists presented prepared ﬁndings on the ﬁrst day
of the conference. Every member of the panel received
equal time to present and to respond to questions from
other panel members. All panel members were required
to submit their presentations before the meeting to
representatives of the Boston University School of
Medicine Department of Continuing Medical Education
(BU CME) to assure that the materials and conference met
standards set forth by the Accreditation Council for
Continuing Medical Education. The meeting itself was not
CME accredited, but the NERI conference organisers felt it
was important to enlist an independent entity to review all
materials for bias and balance before the conference, as well
as having a BU CME representative present during the
conference.
On the second day of the conference, panellists discussed
each of the subject areas presented the previous day until a
consensus was reached and articulated. The panellists
reviewed all key clinical studies relevant to each area. After
the conference, a summary of ﬁndings from the conference
was provided to all panel members for review and approval,
and these ﬁndings provided the basis for this paper.
Results
Defining Nocturia and NP
The ICS in 2002 deﬁned nocturia as ‘waking at night to
void’ [6] (‘Night’ was deﬁned as the period of time between
going to bed with the intention of sleeping and waking
with the intention of arising regardless of when this period
of time occurs).The ICS deﬁnition did not include any
measure or assessment of bother, nor did it diﬀerentiate
between awakenings due to a sensation of the necessity to
urinate from awakenings for other reasons.
In Brief: Key Conclusions of the 2012 Conference
• Questionnaires, e.g. such as the IPSS do not adequately estimate nocturia in most patients, hence frequency-volume
charts (FVCs) should be a required part of any assessment of nocturia.
• Nocturia may have a positive association to mortality, although studies on this topic are contradictory.
• The observed detrimental eﬀects of nocturia on QOL follow a dose-response pattern (i.e. the more frequent the
nocturia, the more severe the impact on QOL).
• Voiding 2 times nightly appears to be the threshold value of nocturia at which nocturia has adverse eﬀects on QOL
and well-being.
• There is a causative relationship between sleep disordered breathing, primarily obstructive sleep apnoea, and
nocturia.
• Nocturia is associated with an increased prevalence of depression, especially in younger men and women.
• The evidence base for determinations of the eﬃcacy of various treatments for nocturia is weak.
• Multi-component behavioural interventions may be attractive for a multifactorial condition such as nocturia despite
the limited evidence base currently available.
• Some primary benign prostatic enlargement (BPE) therapies, e.g. TURP, may reduce nocturia, especially where
obstruction is its main pathophysiology. TURP is reasonably eﬀective in this instance, while the beneﬁt of a-blockers
is less compelling.
• Antimuscarinics as stand-alone therapy are rarely more eﬀective than placebo for reducing nocturia, although they
may be useful for treating overactive bladder (OAB), or as a component of multi-modality therapy where the urgency
component is severe enough to be contributory.
• Antidiuretic therapy appears to be eﬀective in patients with nocturnal polyuria (NP), but safety concerns about
hyponatraemia suggest the need for careful monitoring.
• Women appear to have an increased sensitivity to desmopressin and a lower therapeutic dose may, therefore, achieve
a clinical eﬀect similar to that obtained with a higher dose in men and with a safer therapeutic index.
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Later authors have attempted to narrow the deﬁnition of
nocturia to make the term more clinically meaningful. For
example, evidence suggests that most people with <2
voids/night generally have only minimal bother from the
condition, although some people may be bothered by lower
levels of nocturia if they have diﬃculty falling back to sleep
[7].When 2 voids/night occur on a regular basis,
nocturia is likely to be associated with more serious
consequences for the patient [7]. In addition, as some
panellists noted, the cause of waking is an important
clinical distinction.Waking at night because of a perceived
need to urinate is far more diagnostically relevant to
urological interventions than urinating at night after
awakening from some other cause, although it may be
diﬃcult to make this distinction.
Regardless of its frequency or cause, nocturia results from a
production of nocturnal urine that exceeds the capacity of
the urinary bladder to comfortably store it. As such, an
important part of diagnosis is determining if a patient is
experiencing NP, a greater-than-normal production of
urine during sleep. However, the deﬁnition of NP and the
estimates of ‘normal’ nocturnal urine production, do not
rest on strong evidence. In the course of the NERI
conference, Blanker presented the results of his research
into the deﬁnitions of NP. A PubMed search yielded 58
studies including 16 diﬀerent deﬁnitions of NP, with highly
diverse methods of determining or justifying those
deﬁnitions. Even the most widely-accepted deﬁnition of NP,
from the 2002 ICS panel, was found to be lacking in
scientiﬁc rigour. The ICS deﬁned NP as ‘production of an
abnormally large volume of urine during sleep’ with
‘normal’ urine production varying considerably from
person to person and normally increasing with age [6]. NP
was thus deﬁned as an output of >20% of the daily total
urine production in ‘the young’ and 33% of daily total urine
production in ‘the elderly’ with the value for ‘middle age’
falling somewhere between these two extremes [6].
However, these estimates are based on very small sample
sizes, 18 subjects in the study of ‘young adult’ NP [8] and
45 subjects in the study of ‘elderly’ NP [9]. Applying the ICS
deﬁnition in the general population showed that the
prevalence of NP was high, both in men with nocturia
(92%) and those without nocturia (70%). This is consistent
with the ﬁndings of Swithinbank et al. [10], showing that
only a minority of women with NP have nocturia.
An alternative deﬁnition of NP was used in the Blanker
et al. [11] of 1688 community-dwelling men: nocturnal
urine production of 90 mL/h regardless of a patient’s age
or condition. Using this deﬁnition, Van Doorn et al. [2]
estimated that 28% of the men with nocturia had NP,
compared with 8% of those without nocturia. Based on
these ﬁgures, Blanker estimated that the proportion of
nocturia that is related to the exposure to NP (attributable
proportion) was ª54%, and the proportion of nocturia in
the population that might be attributable to NP (population
attributable proportion) was 15%. The degree to which
nocturia is related to NP, therefore, depends on which
deﬁnition of NP is used.
After a robust discussion of these issues, panellists at the
NERI conference concluded that the original, broad
deﬁnition of nocturia by the ICS 2002 sub-committee
retains utility. Based on the fact that nocturia, by deﬁnition,
results when nocturnal urine production exceeds bladder
capacity, reducing nocturnal urine production in some
manner must be considered for eﬀective therapy. One
might conclude from this argument that a speciﬁc
deﬁnition of ‘abnormal’ nocturnal urine production is not
necessary. Considering the weaknesses noted in the
evidence base used to deﬁne NP in the ICS 2002 guidelines,
the NERI panellists agreed that more research is required
to determine appropriate population-based norms for NP,
as well as for the setting of thresholds for the number of
night-time awakenings that could reliably guide decisions
about which patients might beneﬁt from lifestyle and/or
medical interventions.
Evaluation of Nocturia Outcome Instruments
There is currently no simple, validated self-report
questionnaire or diary measure that allows a practitioner to
determine all of the following important parameters of
nocturia:
• Number of nocturnal voids
• How many nights per week nocturia occurs
• Whether nocturia frequency varies over time
• Why patients perceive that they awakened
• Why patients voided
• How much sleep occurred
• Whether patients fell back asleep
• The degree to which patients are bothered by symptoms
• Whether (and in what way) nocturia symptoms impact
the patient’s quality or quantity of sleep and QOL
Several available questionnaires capture some, but not all,
of the outcomes of interest in the study of nocturia, and
all questionnaires suﬀer from the potential limitation of
recall bias or other diﬃculties (Table 1). For example, a
frequently-reported outcome measure of nocturia
symptoms is question 7 on IPSS: ‘During the last month,
how many times did you most typically get up to urinate
from the time you went to bed at night until the time you
got up in the morning?’. This question is ﬂawed as an
outcome measure in several ways: it asks patients to
mentally average nightly voids over the span of a month;
the question is often misunderstood; and the question fails
to exclude (or deﬁne) the ﬁrst morning void.
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The FVC requires patients to record the volume and timing
of daytime and night-time voids for periods ranging from 1
to 7 days using a calibrated measuring device and a paper
‘diary’. Although valuable and recommended as a key
component of nocturia assessment, FVCs are insuﬃcient
(at least as presently conﬁgured) to capture the level of
detail and qualitative dimensions about nocturia that are
needed for accurate diﬀerential diagnosis of this often
complex condition. The panel concurred that bladder
diaries, which can annotate an FVC, are more relevant for
both research and clinical assessments.
Most short-term bladder diaries (as distinct from FVCs in
which actual volumes are measured) have not been shown
to produce reliable data on the number of nocturnal voids
(Table 2) [12–16]. Seven-day bladder diaries have
acceptable reliability for the number of nocturia episodes,
but such diaries are relatively labour-intensive and, hence,
often suﬀer from poor compliance on the part of patients
[14]. In fact, variation in nocturia severity from night to
night may simply reﬂect ﬂuctuation of nocturnal frequency
during the registration period rather than unreliability of
the diary instrument. Nonetheless, bladder diaries can
provide valuable data and may oﬀer the potential
advantages of helping to distinguish urgency from
non-urgency voids, convenience voids from insomnia
voids, and nocturia from other LUTS.
An ideal assessment tool (or set of tools) would capture the
following outcomes:
1. Primary eﬃcacy outcome
• Number of night-time voids
2. Secondary eﬃcacy outcomes
• Proportion of nights aﬀected
• Nocturnal urine volume
• Maximum nocturnal voided volume
• Why the patient was awakened
• Patient’s perception of why he or she voided
• Whether the patient fell back asleep
3. Bother
4. QOL issues
Panellists agreed on the need to create assessment measures
that fulﬁl these demands, and that this will probably involve
combining data from an FVC with data from a thorough
and well-validated questionnaire and/or bladder diary.
Preliminary work to create a validated ‘urinary diary’ was
recently reported by Bright et al. [16]
Outcomes of Epidemiology
Although nocturia has been thought to aﬀect males
predominantly (because of an assumed relation with
prostate disorders), current evidence shows that nocturia
aﬀects many adults of both genders and in all age ranges
[17]. The prevalence of nocturia (deﬁned as 2
voids/night) clearly increases with age, although it also
manifests in younger people. In a recent review, Bosch and
Weiss (2010) [16] found the following prevalence ranges
(data were not available for patients aged 40–70 years):
• Men aged 20–40 years: 2–17%
• Women aged 20–40 years: 4–18%
• Men aged > 70 years: 29–59%
• Women aged > 70 years: 28–62%
Several studies have found a higher prevalence of nocturia
in both male and female African-Americans [18,19].
This may be due to a higher prevalence among
Table 1 Outcomes assessed by questionnaires pertaining to nocturia.
Questionnaire Efficacy Bother QOL
AUA Symptom Index (AUASI/IPSS) ✓ ✓
Nocturia, Nocturnal Enuresis and Sleep –
interruption Questionnaire (NNES-Q)
✓ ✓
International Consultation on
Incontinence Modular
Questionnaire-Female LUTS
(ICIQ-FLUTS)*
✓ ✓
International Consultation on
Incontinence Modular
Questionnaire-Male LUTS
(ICIQ-MLUTS)
✓ ✓
ICS Male Questionnaire ✓ ✓ ✓
Danish Prostate Symptom Score (Dan –
PSS – 1)
✓ ✓ ✓
Urgency,Weak Stream, Incomplete
Emptying and Nocturia (UWIN)
✓ ✓
Urogenital Distress Inventory (UDI) ✓ ✓
Nocturia Quality of Life Questionnaire
(N-QOL)
✓
International Consultation on
Incontinence Modular Questionnaire
–Nocturia Quality of Life (ICIQ –
NQOL)
✓ ✓
Leicester Impact Scale ✓
International Prostate Symptom Score
Quality of Life Index (IPSS – QOL)
✓
*Previously known as Bristol Female LUTS.
Table 2 Reliability of bladder diaries.
Diary 1-day 2-day 3-day 4-day 7-day
Groutz et al.* [12] <0.6 <0.6 0.69 NA
Brown et al.† [13] 0.7 0.79 0.81
Wyman et al.‡ [14] 0.86
Nygaard et al.‡ [15] 0.887§ 0.887§ 0.906
Bright et al. [16] [Phase I study – no reliability data available]
*Study uses Concordance Correlation Coeﬃcient (acceptable reliability is >0.7);
†Study uses Intraclass Correlation Coeﬃcient (acceptable reliability is >0.75);
‡Study uses Pearson’s correlation coeﬃcient; §Indicates the correlation of the ﬁrst 3
days of the 7-day diary to the last 4 days of the diary.
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African-Americans of conditions associated with nocturia
(i.e. diabetes mellitus, hypertension, sleep apnoea, and
cardiovascular disease), or the inﬂuence of sickle-cell trait
(which may cause renal concentration deﬁcits).
Nocturia is associated with some signiﬁcant comorbid
conditions. Chief among these are insomnia and poor
self-reported sleep quality [20]. In one study, nocturia was
listed as a self-perceived cause of poor sleep four-times
more frequently than the next most-cited cause: pain [21].
Poor sleep and daytime sleepiness have been associated
with the number of nocturia episodes overall, and also with
nocturia episodes after which a person has diﬃculty getting
back to sleep [22]. It is worth noting that chronically
impaired sleep is not just bothersome; it is, in fact,
associated with increased mortality [23,24].
The fear of falling experienced by many older persons
with nocturia is well-founded: most night-time falls are
associated with toilet visits [25]. Nocturia increases the risk
of an incident fall by 25% over 3 years [26]. Fall risk
increases with nocturia frequency; the odds ratio (OR) for a
fall increases from 1.84 with 2 voids/night, to 2.15 with 3
voids/night [21]. Signiﬁcantly, nocturia is associated with
injurious falls, and higher nocturia frequency is associated
with greater risk. The OR for a hip fracture is 1.36 in
older men having 2 voids/night, and 1.80 having 3
voids/night, compared with men without nocturia episodes
[27]. In the latter group, the absolute risk of hip fracture
was 1%.
Outcomes of Evaluation
The multifactorial nature of nocturia has several
implications for its evaluation and management. The usual
practice of history-taking and clinical examination must be
conducted with a consideration of the full range of
potential psychological, socio-economic, and cultural
dimensions of the condition. In addition to the many
physical problems that may be related to nocturia (i.e. OAB,
BPE, congestive heart failure [CHF], and many others),
nocturia may also plausibly be aﬀected by a range of
factors, e.g. sleep disorders, arousal disorders, neurological
conditions, psychiatric conditions, chronic pain disorders,
the use of other medications (e.g. diuretics), use of herbal
or alternative medicine therapies; use of alcohol, caﬀeine or
other substances; or conditions in the home that interrupt
sleep.
Various attempts have been made to capture in algorithm
form this wide range of possible causes as well as the range
of possible outcomes an evaluation for nocturia might
produce. The participants in the NERI conference, after
reviewing several existing algorithms, agreed that the
management algorithm developed by Weiss [28], and
modiﬁed to include some speciﬁc values arising from the
administration of an FVC (or bladder diary containing
information for voided volumes throughout the day/night
cycle), is the most clinically useful of the currently available
algorithms (Fig. 1).
As discussed earlier, FVCs and bladder diaries are
recommended because data obtained from subjective
questionnaires, e.g. the IPSS, have been shown to
overestimate nocturia in most patients [29–31]. The
voiding patterns revealed by FVC and bladder diary data
provide critical guidance for clinicians about the cause
and treatment of nocturia, as can be seen in the four
fundamental FVC outcomes shown in Fig. 1. Based upon
analysis of the FVC/diary data, a patient presenting with
nocturia may have [32]:
1. Low global bladder capacity (indicated by a maximum
voided volume of 200 mL) or low nocturnal bladder
capacity (indicated by a nocturnal bladder capacity of
200 mL or a nocturnal bladder capacity index of 2).
2. NP (indicated by a NP index of >33%, adjusted for age).
3. Polyuria (indicated by a 24-h urine volume of
>40 mL/kg body weight, i.e. 2800 mL for a 70 kg male).
4. Mixed aetiology (any combination of 1, 2, or 3 above)
Each of these potential initial diagnoses will lead a clinician
to further choices of diagnosis and treatment, as
summarised in the algorithm. The critical point to consider
is that the multifactorial nature of nocturia means that
‘mixed aetiology’ may account for the bulk of patient
diagnoses, which suggests that, for many patients, treatment
may involve multiple, incremental, therapeutic
interventions on all levels of a patient’s life to obtain
clinically meaningful improvements in nocturia symptoms
[33].
Medications Contributing to Nocturia/Polyuria
An important contributing factor to nocturia is the eﬀect of
concurrent medication use on urine production, bladder
storage capacity, or both. In the USA, >40% of men aged 
65 years, and 57% of women aged  65 years reported
taking ﬁve or more medications in a given week [34]. Such
polypharmacy greatly complicates the diagnosis and
treatment of nocturia and must be considered at every step
in the continuum of patient care.
Renal homeostasis is complex, with reabsorption of water
and the resulting concentration of urine controlled by
arginine vasopressin (AVP, otherwise known as antidiuretic
hormone), which is released by the posterior pituitary gland
whenever water deprivation causes an increased plasma
osmolality or whenever the cardiovascular system is
challenged by hypovolaemia and/or hypotension. AVP
increases the water permeability of the cell membrane in
the distal nephron, thus permitting water to move passively
Review
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down an osmotic gradient across the collecting duct into
the extracellular compartment (e.g. circulation). Many
classes of medications aﬀect this system in ways that may
manifest as polyuria, NP, or bladder storage dysfunctions
(Tables 3 and 4).
Broadly speaking, medications can cause polyuria in the
following ways:
• Increasing water or liquid intake (polydipsia;
compensation for dry mouth)
• Interfering in renal ability to concentrate urine:
– Diabetes insipidus (central or nephrogenic)
– Solute diuresis impairment of sodium reabsorption
– Carbonic anhydrase inhibition
– Impaired generation of the interstitial osmotic
gradient
• Causing peripheral oedema
Clearly, multiple medications or medication classes may
contribute to nocturia, primarily by inducing polyuria.
Fig. 1 Algorithm for the evaluation of nocturia. NBC, nocturnal bladder capacity; NBCi, nocturnal bladder capacity index; NPi, nocturnal polyuria
index; MVV, maximum voided volume; m0sm/kg, osmolality.
Abbreviations: NBC = nocturnal bladder capacity; NBCi = nocturnal bladder capacity index; NPi = nocturnal
polyuria index; MVV = maximum voided volume; m0sm/kg = osmolality
Low NBC (<200 mL
or NBCi > 2)
Low GBC
(MVV <200 mL)
Frequency-
volume chart
Nocturnal polyuria:
NPi >33%
Polyuria: 24-h
volume >40 mL/kg
Mixed
Overnight water
deprivation
Excessive PM
fluid intake
Peripheral
oedema due
to venous
disease
Primary
polydipsia
Normal
Dx central
diabetes
insipidus
Abnormal
Renal
concentrating
capacity test
Urine <800
m0sm/kg
Urine >800
m0sm/kg
Dx nephrogenic
diabetes insipidus
Chronic renal
failure, lithium,
tetracycline,
hypercalcemia,
hypokalemia
Refer to
endocrinology
Sleep studies
Refer to
cardiology
Congestive
heart failure
Diabetes
mellitus
Look for urological
cause:
• prostatic
obstruction
• nocturnal detrusor
overactivity
• neurogenic bladder
• parmacologic
agents
• bladder/ureteric
calculi
Obstructive
sleep apnoea
suspected
(snoring,
obesity,
short neck)
Multiple
incremental
aetiologies as
per individual
nocturia
categories
Nocturia
Table 3 Medications potentially associated with polyuria/nocturia.
Category Medications
Polydipsia Phenothiazines
Anticholinergics
Central diabetes insipidus Ethanol
Phenytoin (e.g. Dilantin®)
Low doses of morphine
Glucocorticoids
Fluphenazine (e.g. Prolixin®)
Haloperidol (e.g. Haldol®)
Atypical antipsychotics (e.g. risperidone)
Promethazine (e.g. Sominex®)
Oxilorphan
Butorphanol
Nephrogenic diabetes insipidus Lithium
Demeclocycline (e.g. Declomycin®)
Cisplatin (e.g. Platin®)
Amphotericin B (e.g. Fungizone®)
Foscarnet (e.g. Foscavir®)
Ifosfamide (e.g. Ifex®)
Clozapine (e.g. Clozaril®)
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Further research is needed to better characterise the eﬀect
sizes of these medications in relation to nocturia and to
determine dosage levels that may allow such medications to
be used eﬀectively in patients bothered by nocturia.
Outcomes Related to Nocturia and OAB
OAB and nocturia are clearly associated, although the
relationship is not reciprocal: most patients with nocturia
do not have OAB, while many patients with OAB do have
nocturia [35]. In addition, OAB probably plays a relatively
minor role in the genesis of nocturnal voids [36,37]. For
these reasons, antimuscarinics, which reduce night-time
voids due to urgency, do not appear to be eﬃcacious for
most cases of nocturia, although they may be eﬀective for
urgency-related nocturnal voids (fuller discussion later in
this paper).
Outcomes Related to Nocturia and
Sleep Apnoea
The relationship between nocturia and sleep-disordered
breathing, primarily obstructive sleep apnoea (OSA), has
become increasingly apparent in recent years. The causal
connections between these two conditions are compelling.
Community-based elderly populations who have higher
levels of sleep-disordered breathing (in excess of 25
breathing events/h) have nearly double the number of
nocturia episodes as individuals with low rates of OSA [38].
In addition, nocturia confers an ª30% increased risk for
OSA, even after controlling for age, body mass index
(BMI), diuretic use, diabetes, and use of a-blockers [39].
Reduced total sleep time, in turn, correlates with a range of
detrimental eﬀects including increased daytime fatigue,
decreased daytime alertness, increased risk for falls,
depressed mood, cognitive impairment, and decreased
QOL, outcomes that are particularly salient for older adults.
In addition, a 2012 study involving 6342 older subjects
found a clear positive association between nocturia (and
degree of OSA) and cardiovascular mortality, even after
adjustment for known confounders such as age, BMI,
diuretic use, diabetes mellitus, and a-blocker use [39].
Myriad mechanisms may underlie the relationship between
OSA and cardiovascular risk.
In patients with nocturia, OSA should be considered if
there is NP, report of sleep disturbance, snoring or apnoea
(including report by bed partner), daytime somnolence,
hypertension, or morning headache. If apnoea is suspected,
it should become the priority for diagnosis and treatment.
Diagnosis of OSA cannot be made solely based on reported
snoring or fatigue. The American Academy of Sleep
Medicine guidelines recommend that the diagnosis of OSA
be based on clinical signs and symptoms determined
during a comprehensive sleep evaluation, which includes a
sleep-oriented history and physical examination, and
ﬁndings identiﬁed by sleep testing [40].
Nocturia episodes in individuals with OSA may be at least
partially ameliorated by use of one of three primary
treatment options:
• Positive airway pressure (PAP)
• Oral appliance therapy
• Surgery
Of these options, continuous PAP (CPAP) is widely
accepted to be the most eﬀective [40]. Several intervention
studies have found that treatment with CPAP decreases
nocturia [41–43]. A 2012 study of 98 men with moderate to
severe OSA found that treatment with CPAP reduced the
percentage of men reporting nocturia from 38% to 24%
after 6 months [44]. These results support earlier work by
Margel et al. [45], the results of which are summarised in
Fig. 2. Treatment of other primary sleep disorders (e.g.
restless legs syndrome) might also be expected to
ameliorate nocturia episodes if the disorder is the
primary cause of awakening, but this remains untested
to date.
Table 4 Medications known to exacerbate nocturia or polyuria and
their mechanisms of action.
Medications Mechanism of Action
Calcium channel blockers Direct blocking of proximal tubular sodium
reabsorption or increased atrial natriuretic
peptide levels; promote peripheral oedema
and/or pedal oedema
Conivaptan; tolvaptan V2-receptor antagonism
Carbonic anhydrase
inhibitors
Reduced sodium and bicarbonate reabsorption in
proximal tubule
Excessive vitamins A
and D; thiazides
Tubulointerstitial injury secondary to deposition
of calcium in the medulla with subsequent
renal concentrating defects
NSAIDs; thiazolidinedione
anti-diabetic agents,
GABAnergic agents
Promote peripheral oedema and/or dependant
oedema
Source: Weiss JP et al. 2012 [93].
Fig. 2 Comparison of outcomes of 50 patients with mild–moderate
OSA (Respiratory Disturbance Index [RDI] < 35/h) and 47 patients with
severe OSA (RDI > 35/h). Source: Margel et al. 2006 [45].
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Response to Nocturia Therapy: Outcomes
Related to QOL
Although infrequent episodes of nocturia may not be
bothersome for some people, studies to date have shown
that more frequent nocturia can be associated with distress,
discomfort, loss of sleep and signiﬁcant functional
impairment, all of which may erode one’s overall QOL.
Among men who complain of urinary tract symptoms,
nocturia is reported to be the ‘most bothersome’ of such
symptoms [46]. Aﬀected persons describe their nocturia as
‘debilitating, frustrating, distressing, and puzzling’,
particularly in its perceived unpredictability [7]. Older
persons experience a diminished self-image, feel
prematurely ‘old’, and worry about nocturia causing
night-time falls [47]. However, signiﬁcantly some studies
show that the impact on QOL from nocturia-related sleep
fragmentation is more pronounced in younger compared
with older patients, perhaps due to the eﬀects of impaired
productivity in younger persons [48,49].
Studies of the relationship between nocturia and various
aspects of QOL have beneﬁted from the existence of a
validated instrument, the Nocturia Quality of Life
questionnaire (N-QOL), which has been shown to provide
good sensitivity in its ability to discriminate between
subjects with diﬀerent degrees of nocturia severity [50].
However, until recently data have been inconsistent about
the frequency of nocturnal voiding as it aﬀects QOL and
bother. Studies have reported adverse eﬀects from voiding
frequencies of 1, 2, or >2 voids /night (although, as
previously noted, mild nocturia may not be bothersome at
all for many patients) [7,51].
The Boston Area Community Health survey (BACH) of a
random sample of 5503 Boston-area residents has now
shed valuable light on several key aspects of nocturia and
QOL, speciﬁcally, the association between nocturia on QOL
and symptom bother, the association of nocturia with
depression, and whether the association of number of
nightly voids with QOL and depression follows a
severity-response pattern [52]. BACH conﬁrmed the
previously observed association between nocturia and
signiﬁcant decreases in health-related QOL in both sexes
[52]. But BACH has also extended existing knowledge in
several directions. It showed that nocturia is associated with
increased symptom bother and an increased prevalence of
depression, especially in younger men and women (Fig. 3)
[52].
Most signiﬁcantly from a clinical standpoint, the BACH
results showed that the observed detrimental eﬀects of
nocturia on QOL followed a severity-response pattern (i.e.
the more severe the nocturia, the more pronounced the
impact on QOL) and that voiding 2 voids/night was the
threshold value of nocturia beyond with the disorder had
adverse eﬀects on QOL and well-being [52]. Although
causality cannot be drawn from cross-sectional data such as
these, the consistency and magnitude of the observed
associations warrant clinical attention.
Complementing these ﬁndings are results fromWeiss et al.
(2012) [53] showing improvements in QOL scores related
to bother, quality of sleep, and energy levels among patients
whose nocturia was treated pharmacologically. In this study
of 757 patients with nocturia, one less nocturnal void per
night was associated with an increase of 4.68 in the total
N-QOL score (raw QOL scores ranged from 0 to 4 and
were then transformed into a standardised score out of
100). Similarly, a 1-h increase in the ﬁrst period of
undisturbed sleep was associated with an increase of 3.68
in total N-QOL score for bother/concern, and an increase
of 3.27 for sleep/energy. These changes, combined with the
data previously described, lend support to the conclusion
that reducing nocturia may increase a patient’s overall
QOL.
Outcomes Associated with
Management and Treatment
Behavioural Interventions
Patients typically respond to nocturia by engaging in
one or more of the following lifestyle or behavioural
modiﬁcations, motivated perhaps by suggestions in the lay
press, internet, physicians’ oﬃces, or conversation with
friends [1]:
• Pre-emptive voiding.
• Dietary and ﬂuid changes (avoidance of caﬀeinated
beverages, alcohol, etc., especially in the evening).
• Medication timing (diuretics in the mid-afternoon).
• Evening leg elevation to mobilise ﬂuids.
• Use of sleep medications.
• Use of protective undergarments.
Fig. 3.Nocturia and increased risk for depression. Source: Kupelian
et al. 2012 [52].
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Some men may also try herbal supplements, e.g. Saw
Palmetto berry extract, in the belief that nocturia is due to
prostate enlargement. In the USA, for example, between
50% and 90% of men have tried supplements before
seeking medical treatment for their LUTS/BPE [54]. The
studies conducted to date on such supplements; however,
have either been methodologically ﬂawed or have found no
statistical or clinically signiﬁcant beneﬁts [55–58].
In recent years, eﬀorts have been made to evaluate the
eﬃcacy of focused, multi-component behavioural or
lifestyle interventions, either alone or combined with
medical therapies. However, there have been surprisingly
few such studies and those that have been conducted have
been uncontrolled, impairing the ability to draw ﬁrm
conclusions about treatment eﬀects. A behavioural study of
24 patients with OAB, for example, found that reducing
ﬂuid intake by 25% resulted in a statistically, but not
clinically, signiﬁcant reduction in nocturia ‘episodes’ from a
mean of 1.4 voids/night to 1.3 voids/night [59]. An attempt
to get patients in this study to reduce their ﬂuid intake by
50% did not meet its goal, patients were only able to reduce
intake by a mean of 32%, which reduced nocturia episodes
from 2.3 to 1.8 voids/night after 4 days.
A Japanese trial of a multi-component lifestyle
modiﬁcation regimen that included restriction of ﬂuid
intake, refraining from excess hours in bed, moderate daily
exercise, and keeping warm in bed showed a reduction in
mean nocturnal voids from 3.6 to 2.7 and a decrease in
mean nocturnal urine volume from 923 to 768 mL after
4 weeks [60]. Of the 56 patients in the study, 53% showed
an improvement of >1 void/night, with the intervention
being more eﬀective in patients with greater polyuria at
baseline.
A more recent study of a multi-component lifestyle
intervention for 82 patients with NP involved a 30-min
patient education/behaviour modiﬁcation programme,
regulation of ﬂuid intake, and regular meetings/discussions
with a nurse-practitioner [61]. The authors reported that
mean nocturnal voids decreased from 2.6 at baseline to 1.1
voids/night over the course of the study, interestingly with
no statistically signiﬁcant change in measures of nocturnal
urine volume.
A 4-week uncontrolled study combining a
multi-component behavioural intervention with targeted
use of terazosin (an a-adrenergic antagonist used for
treatment of voiding LUTS) and the sedative/hypnotic
zaleplon found that mean diary-recorded nocturia
decreased from 2.6 to 1.9 and the bother score reduced
from 3.1 to 1.1 voids/night [62]. The study authors deemed
these results ‘promising’, although with the caveat that the
study should be repeated with a randomised, controlled
trial.
Burgio et al. [63] conducted a randomised controlled
equivalence trial of 143 men with LUTS who had persistent
urgency and >8 daily voids (despite a 4-week run-in period
using an a-adrenergic antagonist). Men were randomised
to receive either 8 weeks of behavioural treatment
(consisting of pelvic ﬂoor muscle exercises, urge
suppression techniques, and delayed voiding) or treatment
with an individually titrated extended-release
antimuscarinic (oxybutynin, 5–30 mg/day). There were
no statistically signiﬁcant between-group diﬀerences in
mean voids per day or self-reports of satisfaction or
improvements in symptoms. The behavioural group had a
mean reduction in nocturnal episodes of 0.70, which was
statistically signiﬁcantly greater than the mean reduction of
0.32 for those in the drug therapy group (P = 0.05). The
drug therapy group showed greater reductions in
maximum urgency scores (mean reduction of 0.44 vs 0.12,
P = 0.02) as measured by the AUA Symptom Index.
Panellists concluded that multi-component interventions
are an attractive approach to a multifactorial condition
such as nocturia, despite the relative paucity of supporting
data.
Diuretic Treatment of Nocturia
Paradoxically, diuretics are associated with a greater risk of
nocturia [64] even though they are sometimes used as
pharmacotherapy for nocturia. At least part of the
explanation lies in the fact that the indications for diuretic
treatment (e.g. oedema, CHF, OSA) are independently
associated with nocturia. In addition, diuretics are often
prescribed for peripheral oedema with no particular
attention to the time of day at which they would be most
eﬀective. This may cause or exacerbate nocturia in patients
with NP owing to reabsorption of lower extremity ﬂuid
during recumbency. In such patients, diuretics should be
administered during the mid-afternoon to address ﬂuid
accumulated over the course of the day, but not so late as
to exacerbate NP [65,66].
After reviewing the few studies of diuretics as a treatment
for nocturia, either alone or combined with other
medications, panellists concluded that loop and thiazide
diuretics may decrease nocturia episodes, with relatively
greater decreases in NP. But the quality of existing studies is
generally poor to moderate, the trials have been small and
short term, many have not been ‘blinded’, and the eﬀects of
diuretic therapy for nocturia on renal function and
electrolytes has not been assessed.
In addition, there is insuﬃcient evidence on which to
decide which patients might beneﬁt most from diuretic
therapy (although panellists acknowledged that this
diﬃculty applies more broadly because of a lack, to date, of
methods to sub-categorise patients with nocturia). Of
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course, decreasing night-time urine volume will not likely
have any eﬀect for patients whose night-time voiding is out
of convenience when awakened by something other than
the need to void. These conclusions are consistent with the
recommendations of the Committee for Establishment of
the Clinical Guidelines for Nocturia of the Neurogenic
Bladder Society, which ranked the evidence from existing
nocturia studies involving azosemide, bumetanide, and
furosemide (frusemide) as Level 2 with a Grade C
recommendation [67].
BPE Therapy and Nocturia
Because BPE is highly associated with nocturia, much
attention has been devoted to exploring whether treatments
for BPE may improve symptoms of nocturia. A range of
treatments has been investigated in this regard, including:
• a-adrenergic antagonists.
• 5a-reductase inhibitors (5ARIs).
• Combined a-adrenergic antagonist and 5ARI therapy.
• Botulinum toxin.
• NSAIDS.
• Surgery.
The results from the most recent studies of each of these
agents, in relation to nocturia, are summarised in Table 4.
Although much of the evidence reviewed above is limited
by the use of nonspeciﬁc outcome measures for evaluating
nocturia symptoms (e.g. IPSS or AUA-7), and
methodological weaknesses (i.e. not ‘blinded’, uncontrolled),
it does suggest that speciﬁc nocturia outcomes might by
positively aﬀected by some primary BPE therapies,
primarily 5ARIs, botulinum toxin-A, and TURP. In
contrast, and as summarised in Table 5 [68–79], available
evidence suggests only modest eﬃcacy for a-adrenergic
antagonists and NSAIDs. Continuing research in these
areas will be improved only if more speciﬁc and validated
nocturia outcome measures are incorporated into study
methodologies.
Antimuscarinics for Nocturia
As reviewed in detail in the 2011 consensus paper [1],
antimuscarinic therapy has been repeatedly explored as a
treatment approach for nocturia. As antimuscarinics exert
no eﬀect on NP, these agents may reduce nocturia
symptoms by increasing bladder capacity, which may
beneﬁt patients whose awakenings are associated with
urgency. The data summarised in the previous consensus
paper support this expectation, with the signiﬁcant caveat
that even studies showing statistically signiﬁcant
improvements with an antimuscarinic in the sub-group
of nocturia patients with OAB, may not, in fact, be
demonstrating any clinically signiﬁcant diﬀerences [80–84].
Results of recent studies do not support any change in
these conclusions. Ginsberg et al. [85], for example, studied
once-daily administration of trospium chloride (extended
release, XR) against placebo for nocturnal and diurnal
symptoms of OAB in two phase III trials. After 12 weeks,
the group on trospium XR was found to have a statistically
signiﬁcantly greater mean reduction from baseline in
nocturnal voids (-0.8 vs -0.6; P = 0.006) and diurnal voids
(-1.9 vs -1.4; P < 0.001). Although this result was deemed
enough to justify a conclusion that trospium XR
‘signiﬁcantly improved both nocturnal and diurnal OAB
symptoms’, the consensus panellists doubted that the
reported reduction of 0.2 voids/night with the medication
held any real clinical value.
The conclusion of the panel was that antimuscarinics as
stand-alone therapy are minimally more eﬀective than
placebo for reducing nocturia, although they may be useful
for treating OAB, or as a component of multi-modality
therapy where the LUT problem is severe enough to be
contributory, as in cases involving severe nocturnal OAB
episodes.
Antidiuretic Therapy for Nocturia
At present, the only antidiuretic therapy indicated
speciﬁcally for nocturia is the synthetic analogue of AVP,
desmopressin. Desmopressin is a selective V2 receptor
agonist, and therefore has a greater speciﬁcity of action
than AVP, avoiding unwanted vasopressor and uterotonic
eﬀects associated with V1 agonism [86]. Desmopressin has a
more powerful and longer-lasting antidiuretic action than
AVP. It increases reabsorption of water in the distal and
collecting tubules of the kidney via its action on the V2
receptor, thereby concentrating urine, decreasing urine
production, and postponing the need to void.
Several randomised placebo-controlled trials have shown
the eﬃcacy of oral desmopressin in the treatment of adults
with nocturia [86–88]. A series of 3-week, randomised,
double-blind, placebo-controlled trials showed that oral
desmopressin (0.1, 0.2 or 0.4 mg tablet) is eﬀective in both
men and women aged  18 years with nocturia. In these
studies, clinical response was deﬁned as 50% reduction
in nocturnal voids from baseline. Regarding safety,
hyponatraemia is a potentially serious adverse event
associated with desmopressin use. In one study of 632
patients receiving desmopressin for nocturia, 31 (4.9%) had
signiﬁcant hyponatraemia, with risk rising with age and the
presence of low serum sodium at baseline [89]. Initiation of
desmopressin is therefore currently not indicated for
patients aged  65 years. The mechanisms behind
desmopressin-induced hyponatraemia have been
extensively studied, and panellists concluded that serum
sodium monitoring at baseline and early in treatment
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(within 1 week of dose initiation) in older patients
can substantially reduce their risk of developing
hyponatraemia. An exact scheme for sodium monitoring,
particularly in frail elderly patients, has yet to be
determined.
Several recent studies have produced evidence for a gender
diﬀerence in sensitivity to desmopressin. Animal studies
have suggested genetic diﬀerences related to expression of
the V2 receptor [90], and clinical trials have shown that
women appear to have an increased sensitivity to
desmopressin [91,92]. It is likely, therefore, that a lower
therapeutic dose for women may provide the same degree
of clinical eﬀect as a higher dose in men [93].
Several research groups are exploring a range of novel V2
receptor agonists for their antidiuretic activity with
in vitro tests, animal models, and human trials [94]. A
representative example is the oral non-peptide compound
VA106483. A double-blind placebo trial in 27 men aged >
65 years with nocturia showed that mean diuresis decreased
in those receiving VA106483, and that the duration of
Table 5 Recent study results of selected BPE therapies related to nocturia.
Class Study Study design N Nocturia results
a blockers Zhang et al.
2011 [68]
Prospective, randomised, open
comparison of doxazosin
gastrointestinal therapeutic system
(GITS) 4 mg and tamsulosin 0.2 mg
189 Mean nocturia reduction doxazosin-GITS vs tamsulosin on FVC (1.7 vs
1.3 voids/night at week 4; 2.1 vs 1.7 voids/night at week 8, both P =
0.001), IPSS-question 7 (1.5 vs 1.1 at 4 weeks, P = 0.001; 2.0 vs 1.6 at 8
weeks, P < 0.001).
Lojanapiwat
et al, 2011
[69]
8-week, open-label study of oral
tamsulosin for LUTS
51 Total IPSS signiﬁcantly decreased from 19.52 to 6.08 (P < 0.001).
IPSS-QOL and N-QOL scores signiﬁcantly improved at visit 3 through
to the end of study. Signiﬁcant nocturia and hours of undisturbed
sleep improvement at last clinic visit.
Yoshida et al.
2010 [70]
8-week study of tamsulosin in patients
with nocturia associated with
LUTS/BPE
160 97 patients ‘responders’ based on FVC data. In this group, nocturnal
voiding frequency decreased from 3.1 to 1.7 voids/night (P < 0.001);
nocturnal urine volume decreased from 712.5 to 533.3 mL (P < 0.001);
and hours of undisturbed sleep increased from 2.1 to 3.5 h (P < 0.001).
Curran, 2011
[71]
Analysis of three 12-week randomised,
double-blind trials of silodosin vs
placebo (2 trials) or tamsulosin (1 trial)
1878 (sum
of 3 trials)
Silodosin signiﬁcantly more eﬀective than placebo or tamsulosin in
simultaneously improving nocturia, frequency and incomplete
emptying.
Vallancien
et al. 2008
[72]
3-year open-label eﬃcacy and safety study
of alfuzosin 10 mg/day in men with
LUTS
689 Signiﬁcant (P < 0.001) improvements from baseline in nocturia (–0.8,
–25.5%) and bother score (–1.7, –40.7%).
5ARIs Tacklind
et al. 2010
[73]
Cochrane systematic review NA Doxazosin and terazosin signiﬁcantly more likely than ﬁnasteride to
improve peak urine ﬂow and nocturia. No signiﬁcant diﬀerence with
tamsulosin.
Combined
therapy
Yang et al.
2007 [74]
6-week randomised comparison study of
terazosin 2 mg/day vs terazosin
2 mg/day and tolterodine 2 mg/twice
daily
191 IPSS scores for urgency, frequency and nocturia signiﬁcantly improved
in both groups, although score reduction in the combined therapy
group was signiﬁcantly greater (P < 0.01). Diﬀerences in peak urinary
ﬂow rate and residual urine from the baseline not signiﬁcant between
the two groups. Incidence of adverse eﬀects higher in the combined
therapy group.
Kaplan et al.
2007 [75]
12-week pilot study of alfuzosin
10 mg/day, sildenaﬁl 25 mg/day, or
combination of both on LUTS and
erectile dysfunction
62 IPSS score improvement signiﬁcant in all three arms, greatest with
combination (–24.1%) compared with alfuzosin (–15.6%) and sildenaﬁl
(–11.8%). Frequency of nocturia, post-void residual urine volume, and
maximum urinary ﬂow rate signiﬁcantly improved with alfuzosin only
and the combination.
Botulinum
toxin-A
injection
Madani et al.
2012 [76]
Open-label pilot study 10 Mean (SD) nocturia events decreased from 4.1 (0.87) to 2.4 (0.84)
voids/night (P < 0.001) after mean duration of follow-up of 7.5
months.
NSAIDs Shin et al.
2011 [77]
12-month comparison of nocturia
patients. Group 1 received a-blocker,
5ARI and loxoprofen 60 mg/day.
Group 2 received a-blocker and 5ARI
only.
78 At 6 and 12 months, nocturia episodes decreased signiﬁcantly compared
with baseline in both group I and group II (P < 0.05), but the degree of
decrease was not signiﬁcantly diﬀerent between the groups (P > 0.05).
Long-term use of loxoprofen not recommended because of side-eﬀects
(gastric discomfort/leg oedema).
Falahatkar
et al. 2008
[78]
1-month randomised, double-blind study
of men with LUTS/BPH comparing
celecoxib 100 mg/day vs placebo
80 Nocturnal voiding frequency decreased from 5.17 to 2.5 voids/night in
celecoxib group, vs 5.3 to 5.12 voids/night in placebo group (P <
0.001). IPSS scores decreased from 18.2 to 15.5 in celecoxib group, vs
18.4 to 18 in placebo group. Celecoxib eﬀective in treatment of
patients with BPH complaining of refractory nocturia.
Surgery Simaioforidis
et al. 2011
[79]
Randomised comparison of tamsulosin
0.4 mg/day or TURP in men with
LUTS/BPH
66 At the 3-month and 1-year follow-ups both tamsulosin and TURP
improved all examined parameters. TURP was associated with a
statistically signiﬁcant improvement in the number of nocturnal
awakenings and in the IPSS, ICIQ-N and ICIQ-NQOL scores
compared with tamsulosin. Hours of undisturbed sleep increased in
both groups without any statistically signiﬁcant diﬀerence.
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antidiuretic action increased in a dose-dependent manner
[95].
Surgical Management of Nocturia
Current evidence does not support nocturia as a primary
indication for the use of outlet obstruction-relieving
surgery, because nocturia is the least speciﬁc symptom of
BPE and is the least responsive LUTS for therapies directed
at alleviating prostatic obstruction [96]. The fact that
nocturia may improve after surgery for BPO, does not
signify that BPO surgery is mandated for men presenting
with nocturia. The absence of randomised trials of outlet
surgery on nocturia outcomes makes assessment of eﬃcacy
diﬃcult [97]. In addition, the most-frequently-reported
outcome measure of nocturia symptoms in studies
involving surgical interventions is question seven on the
IPSS, which, as previously mentioned, is ﬂawed in ways
that make it diﬃcult to draw ﬁrm conclusions about
eﬃcacy.
Also unclear is what mechanism/mechanisms, explain some
of the studies showing a beneﬁt for patients with nocturia
of various types of surgery. For example, Anetunes et al.
[98] reported that the positive eﬀects of TURP on nocturia
were not correlated with the amount of resected tissue.
Proposed mechanisms for beneﬁts of surgical outlet
reduction include:
• Resolution of detrusor overactivity with reinnervation of
the bladder after removal of an obstruction [99].
• Destruction of prostatic/bladder neck urothelium leading
to a ‘deaﬀerentation’ of neurones that initiate involuntary
detrusor contractions [100].
• Lower post-void residual urine volume, allowing
increased time for bladder ﬁlling [101].
However, at present, insuﬃcient data exist to support any
of these theorised mechanisms.
A conclusion of the 2011 consensus paper that TURP
appears to confer a greater improvement in LUTS due to
BPE than either transurethral microwave treatment or oral
a-adrenergic blocker therapy has been reinforced by a
recent trial by Simaioforidis et al. [79]. Men with untreated
LUTS were randomised to the a-blocker tamsulosin 0.4 mg
(n = 33) or TURP (n = 33). TURP conferred signiﬁcant
beneﬁts in number of nocturnal awakenings, IPSS,
International Consultation on Incontinence Questionnaire
Nocturia (ICIQ-N), and ICIQ-Nocturia Quality of Life
(NQOL) scores vs tamsulosin. The authors concluded that
TURP is superior to tamsulosin for the management of
BPE-related nocturia. These results are consistent with
previously-reported studies suggesting superiority for
TURP for nocturia symptoms [98,101–103]. Improvements
in nocturia symptoms have also been reported with laser or
microwave ablation techniques [100,104,105].
A recent study by Hutchinson et al. [106] highlights the
variability in nocturia outcomes that may be expected from
radical prostatectomy. This study of 116 men with clinically
localised prostate cancer tracked nocturia symptoms for
1 year after robot-assisted laparoscopic prostatectomy
(RALP). RALP was associated with improved symptoms in
patients who had more severe pre-intervention nocturia;
interestingly, some patients with minimal preoperative
nocturia had a worsening of their nocturia postoperatively
(Table 6) [106].
Conclusions and Future Directions
The awareness of and degree of clinical attention paid to
nocturia has expanded signiﬁcantly in the past decade. In
2000, nocturia was not recognised as a distinct condition,
but was, rather, seen as part of an array of symptoms
associated with other diseases such as OAB or BPE. It had
often been considered to be a normal component of ageing
that primarily aﬀected men. Further, there was no
standardised deﬁnition or terminology to describe nocturia.
Nocturia is now viewed as a distinct medical condition in
its own right, with NP being recognised as a frequent
ﬁnding in patients with nocturia (although NP may also be
present in patients without nocturia).
Nocturia is now understood to aﬀect men and women
equally. Although clearly associated with ageing, nocturia
may, in fact, be signiﬁcantly burdensome for younger
patients. As summarised in this paper, there is also now a
better appreciation for the relative ineﬀectiveness of many
therapies directed at the LUT.
The treatment of nocturia continues to evolve, and the
multifactorial nature of nocturia suggests an approach
involving incremental treatments targeting individual
pathophysiological states such as antidiuretic therapy
for NP, antimuscarinics for nocturnal urgency, and
medical/surgical therapy of the bladder outlet in cases of
nocturia related to infravesical obstruction.
Table 6 Nocturia outcomes after RALP.
Preoperative Postoperative, %
0–1
nocturnal
voids
2
nocturnal
voids
≥3
nocturnal
voids
0–1 nocturnal voids (n = 63) 78 21 2
2 nocturnal voids (n = 29) 52 34 14
3 nocturnal voids (n = 24) 29 38 33
Source: Hutchinson et al. 2012 [106].
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Panellists noted that the ﬁeld of nocturia remains relatively
under-researched and, in addition to previously articulated
needs for more research, the following nocturia-related
issues require investigation in the future:
• Clariﬁcation and validation of the deﬁnitions of both
nocturia and NP and of methods to distinguish
volume-related, bladder-related, and convenience voids.
• The relationship between nocturia and obesity, ﬂuid and
sodium intake, cardiovascular disease, and kidney disease.
• Evaluation of outcomes of multi-modal therapy of
nocturia.
• Improved strategies for diagnosis and treatment of low
bladder capacity as a cause of nocturia.
• Better deﬁnition and criteria for measurement of
nocturnal urgency.
• Whether antidiuretic therapy should be limited to
patients with diary-conﬁrmed NP.
• The need for clinical trials of nocturia treatments on
objective measures of sleep.
• Age-related changes in circadian rhythms.
• Whether there are any unfavourable outcomes of
nocturia therapy such as falls, fractures, mortality, and
costs to society, and whether there are correlations
between improvements in nocturia and decreased risk of
adverse eﬀects secondary to interrupted sleep.
• Better characterisation of nocturia symptoms that are
signiﬁcant or meaningful from the patient’s perspective
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